8-K: Longevity Health Amends True Health Merger Terms

Longevity Health Holdings, Inc. amended its merger agreement with True Health Inc. to adjust the calculation of merger and earnout shares based on a market price floor.

Summary

• Longevity Health Holdings, Inc. (the Company) previously entered into an Agreement and Plan of Merger (the Merger Agreement) with True Health Inc. (True Health) and Truehealth Management Group LLC (TMG) on July 14, 2025.
• The Merger involves THP Sub, Inc. (Merger Sub), a wholly-owned subsidiary of Longevity, merging with True Health, resulting in True Health continuing as a wholly-owned subsidiary of Longevity.
• Longevity will also acquire TMG's right, title, and interest in FDA authorizations, approvals, licenses, permits, certificates, registrations, or exemptions required for True Health's products.
• On November 3, 2025, the Company, True Health, Merger Sub, and TMG amended the Merger Agreement.
• The amendment modifies the calculation of "Merger Shares" to be the number of shares of Longevity's common stock determined by dividing $59,000,000 by the lesser of the "Parent Market Price" and $3.00.
• The amendment modifies the calculation of "Earnout Shares" to be the number of shares of Longevity's common stock determined by dividing $20,000,000 by the lesser of the "Parent Market Price" and $3.00.
• The "Parent Market Price" is defined as the volume average weighted closing sale price of Longevity's common stock during the 15 consecutive full trading days immediately preceding the effective time of the Merger.

Sentiment

Score: 6

Explanation: The amendment indicates progress on the merger, which is generally positive for deal completion. However, the specific terms of the share calculation (using the "lesser of Parent Market Price and $3.00" in the denominator) appear to be more dilutive for Longevity's existing shareholders under various market price scenarios, introducing a slight negative sentiment for current shareholders. The extensive list of risks also tempers enthusiasm.

Positives

• The amendment indicates continued progress towards the completion of the merger, signaling commitment from all parties.
• The inclusion of a $3.00 effective price cap for the share calculation (if the market price is higher) ensures that True Health/TMG shareholders receive a certain minimum number of shares based on a $3.00 valuation, which could be seen as beneficial for the acquired entity.

Negatives

• The amendment introduces terms that could lead to greater dilution for Longevity's existing shareholders. If Longevity's common stock trades above $3.00, the number of shares issued for the merger and earnout will be calculated using an effective price of $3.00, meaning more shares will be issued than if the actual higher market price was used.
• If Longevity's common stock trades below $3.00, the number of shares issued will be based on the actual lower market price, also leading to greater dilution for existing shareholders compared to a fixed share amount.

Risks

• Inability to obtain regulatory approvals required to consummate the Merger on the terms expected, at all, or in a timely manner.
• Failure of conditions to the Closing and the ability of the parties to consummate the Merger on a timely basis or at all.
• Failure of the Merger to deliver the estimated value and benefits expected by the Company.
• Incurrence of unexpected future costs, liabilities, or obligations as a result of the Merger.
• The effect of the announcement of the Merger on the ability of the Company or True Health to retain and hire necessary personnel and maintain relationships with material commercial counterparties, consumers, and others.
• The inability of the Company to successfully integrate True Health's operations over time.
• The inability of the Company to successfully implement its plans, forecasts, and other expectations with respect to True Health's business after the Closing.
• Risks related to the market price of the Company's common stock relative to the value suggested by the Parent Market Value.
• Risks related to the parties' ability to obtain a listing on The Nasdaq Stock Market LLC for the combined company upon the closing of the Merger.
• Risks related to the Company's ability to manage its operating expenses and its expenses associated with the proposed Merger pending the Closing.
• Other risks and uncertainties inherent in a transaction of this size and nature.
• The general strength of the economy and other economic conditions.
• Risks related to the diversion of management's attention from the Company's ongoing business.
• The inability to recognize anticipated benefits from commercial products, R&D pipeline, and distribution agreements.
• Changes in applicable laws or regulations.
• Other risks and uncertainties described in the Company's Annual Report on Form 10-K filed on March 31, 2025, and in other reports filed with the SEC.

Future Outlook

The filing contains forward-looking statements regarding the anticipated benefits and impact of the Merger and License Purchase on the combined company's business, future financial and operating results, and operational goals, plans, and projections. However, it explicitly cautions that these statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results.

Management Comments

• "Although the Company believes that it has a reasonable basis for each forward-looking statement contained in this Current Report, the Company cautions you that these statements are based on a combination of facts and factors currently known by it and its projections of the future, about which the Company cannot be certain."
• Rajiv Shukla, Chairman and CEO of Longevity Health Holdings, Inc., signed the amendment.
• George Chi, CEO of True Health Inc. and Truehealth Management Group LLC, signed the amendment.

Industry Context

This amendment is specific to a single merger transaction in the health/longevity sector. It reflects ongoing M&A activity and the complexities of valuation adjustments in such deals, particularly when involving stock-based consideration and earnouts. The focus on FDA authorizations suggests a company operating in a regulated healthcare or biotech space.

Stakeholder Impact

• Shareholders (Longevity Health Holdings, Inc.): The amended share calculation terms introduce a potential for increased dilution. If the Parent Market Price is above $3.00, more shares will be issued than if the actual higher market price was used (as the calculation uses $3.00 as the denominator). If the Parent Market Price is below $3.00, shares will be issued based on the actual lower market price, also leading to greater dilution compared to a fixed share amount.
• Shareholders (True Health Inc./TMG): The amendment provides a mechanism for calculating the number of shares they will receive, with an effective cap on the share price used for calculation at $3.00, which could result in receiving more shares if Longevity's stock performs well.
• Employees: The merger could impact personnel retention and hiring at both companies.
• Commercial Counterparties/Consumers: The merger could affect relationships with these parties.

Next Steps

• Obtain regulatory approvals required to consummate the Merger.
• Satisfy or waive conditions set forth in the Merger Agreement.
• Consummate the Merger.
• File relevant materials with the SEC, including Form S-4, Proxy Statement, and prospectus, in connection with the proposed Merger.
• Obtain a listing on The Nasdaq Stock Market LLC for the combined company upon the closing of the Merger.

Key Dates

Recommendation

The amendment clarifies the share calculation for the ongoing merger, which is a step towards completion. However, the terms of the amendment appear to be more dilutive for existing Longevity shareholders under various market price scenarios, introducing uncertainty regarding the ultimate impact on per-share value. The extensive list of risks associated with the merger also warrants caution. A "Hold" recommendation is appropriate until the full financial implications and integration progress become clearer.

Keywords

Merger Agreement Amendment, Longevity Health Holdings, True Health Inc., THP Sub Inc., Truehealth Management Group LLC, SEC Filing, 8-K, Corporate Acquisition, Stock Valuation, Earnout Shares, Merger Shares, Parent Market Price, FDA Authorizations, Nasdaq Listing